At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,866 enrolled
Drug / intervention
13-valent Pneumococcal Conjugate Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Vaccine Serotypes of Streptococcus Pneumoniae in Healthy Infants in Israel.
In Brief
A Phase 3 clinical trial evaluating 13-valent Pneumococcal Conjugate Vaccine and 7 valent pneumococcal conjugate vaccine for Pneumococcal Infections. Completed, enrolled 1,866 participants across 5 sites.
Detailed Summary
This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Infections
CountriesIsrael
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartDec 2007
Primary CompletionAug 2011
TodayJul 2026
First PostedJul 30, 2007
Enrollment StartDec 1, 2007
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.9 years ago
Interventions
13-valent Pneumococcal Conjugate Vaccinebiological
1 dose at 2, 4, 6 and 12 months of age
7 valent pneumococcal conjugate vaccinebiological
1 dose at 2, 4, 6 and 12 months of age